The estimated Net Worth of Elliot Norry is at least $123 Тысяча dollars as of 16 January 2024. Elliot Norry owns over 20,563 units of Adaptimmune Therapeutics Plc stock worth over $20,798 and over the last 5 years he sold ADAP stock worth over $102,091. In addition, he makes $0 as Senior Vice President и Chief Medical Officer at Adaptimmune Therapeutics Plc.
Elliot has made over 12 trades of the Adaptimmune Therapeutics Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 20,563 units of ADAP stock worth $14,188 on 16 January 2024.
The largest trade he's ever made was selling 20,563 units of Adaptimmune Therapeutics Plc stock on 16 January 2024 worth over $14,188. On average, Elliot trades about 3,471 units every 86 days since 2020. As of 16 January 2024 he still owns at least 19,257 units of Adaptimmune Therapeutics Plc stock.
You can see the complete history of Elliot Norry stock trades at the bottom of the page.
Dr. Elliot Norry M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Norry serves as Senior Vice President, Chief Medical Officer of the Company. Elliot Norry serves as Senior Vice President, Chief Medical Officer of the Company. Elliot Norry serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Norry has served as Head of Clinical Safety and Pharmacovigilance and leader of the ADP-A2AFP program since 2015. He has been acting Chief Medical Officer since August 2019. Prior to joining Adaptimmune, he served as Safety Development Leader and was Chair of the Hepatic Safety Panel at GSK. Prior to his work in the biotech and pharmaceutical industries, Dr. Norry practiced adult internal medicine at Abington Memorial Hospital in Abington, Pennsylvania for 13 years. He holds a B.A. from Columbia College and an M.D. from New York University. He performed his residency in Internal Medicine at Temple University Hospital, Philadelphia and GI fellowship at Thomas Jefferson University Hospital, Philadelphia.
Elliot Norry is 57, he's been the Senior Vice President и Chief Medical Officer of Adaptimmune Therapeutics Plc since 2020. There are 4 older and 14 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.
Elliot's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.
Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over $40,532,026 worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth $527,131,726 . The most active insiders traders include Forest Baskett, Scott D Sandell и Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of $2,827,332. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth $22,814.
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include: